PGT-M Explained: Single-Gene Testing Before Embryo Transfer

Medically reviewed on 11 November 2026 - Dr. Senai Aksoy
Illustration of a couple sitting at a wooden table and looking together at a printed report, in a quiet room with grey walls and a brass lamp

Key Takeaways

PGT-M combines IVF, a biopsy of the day-5 or day-6 embryo (blastocyst) and a lab test built around a known single-gene (monogenic) variant in the family. It lowers the chance of transferring an embryo affected by that one condition. It cannot predict implantation or live birth, and it does not rule out other genetic or health risks.

Key evidence: ASRM committee opinion: indications and management of PGT-M (2023) ESHRE good practice recommendations for monogenic PGT (2020) ACOG committee opinion: preimplantation genetic testing (2020)

PGT-M: How to Reduce the Risk of Passing On a Serious Genetic Condition

PGT-M: How to Reduce the Risk of Passing On a Serious Genetic Condition

This video was recorded in French. English and Arabic dubbed audio and subtitles are available from the YouTube player settings.

When a family already knows which gene variant is involved, the question is rarely “Can we screen for everything?” It is narrower. How far can we lower the chance of passing on this inherited condition, within the real limits of IVF?

PGT-M (preimplantation genetic testing for monogenic, or single-gene, disorders), historically called PGD, is built for that purpose. The laboratory designs a test around the family’s variant and, where needed, validated linked markers. This helps select embryos for one defined condition. The test does not replace genetic counselling, follow-up during pregnancy or a realistic discussion of what IVF can achieve.

What is PGT-M?

PGT-M is a targeted DNA test on a few cells taken from an embryo, usually at the blastocyst stage (day 5 or day 6 of development). It checks whether the embryo has inherited a specific, known single-gene variant, so the clinical team can prioritise unaffected embryos for transfer.

The procedure sits on top of a standard IVF cycle: ovarian stimulation, egg retrieval, fertilisation and extended culture in the laboratory. Once an embryo reaches the blastocyst stage, an embryologist performs a trophectoderm biopsy. This means removing 5 to 10 cells from the outer layer, which goes on to form the placenta (ESHRE recommendations, 2020). The cells are analysed with a test designed around your family’s variant.

According to the ASRM Practice Committee guidance (2023), PGT-M can reduce the chance of transferring an embryo affected by the targeted disorder. Its scope is narrow. It does not routinely assess chromosome copy number, which is the separate question PGT-A addresses, and it cannot predict implantation or live birth (a baby born alive).

Who is it used for?

PGT-M is considered when one or both partners carry a confirmed pathogenic (disease-causing) variant that poses a significant risk of a severe inherited disease in their children.

It is commonly considered for:

In Turkey, PGT-M is assessed according to the medical indication and within the regulations in force. Genetic testing done only to determine sex, without a medical indication, is not allowed. The embryo’s sex is not stated on a PGT report unless a sex anomaly is involved (the regulation’s wording is “cinsiyet anomalisi”) (Official Gazette regulation, 24 October 2025, Art. 22/1-n). The assisted reproduction regulation separately bars choosing or transferring gonads or embryos to determine a child’s sex, except to avoid a serious hereditary disease related to sex (Annex 17, item 8). PGT-M is scientifically feasible for hereditary cancer predisposition, such as familial BRCA1/BRCA2 variants, but not every predisposition is automatically an accepted indication in Turkey. In X-linked inherited diseases, the aim is to prevent the disease from being passed on, not to choose a sex by preference. The reimbursement list of the Social Security Institution (SGK) does not, on its own, determine which PGT-M applications can legally be performed.

The laboratory usually needs a clear molecular genetics report before it can design the test. A consumer screening result alone may not give the variant details or family information that PGT-M requires. Depending on the case, the laboratory may also ask for samples from relatives whose genetic status is known, so that it can establish linkage.

How does the PGT-M process work?

The pathway has seven stages and links clinical embryology with molecular genetics:

StepClinical PhaseWhat Happens
1Pre-cycle assay designGenetic counselling, validation of familial variants, design of targeted probes and linkage markers
2Ovarian stimulation & retrievalHormonal stimulation followed by egg retrieval under mild sedation
3Fertilisation & cultureFertilisation in the IVF laboratory, often by ICSI when the laboratory protocol needs to minimise extraneous sperm DNA; culture to a day-5 or day-6 blastocyst
4Trophectoderm biopsyRemoval of 5–10 trophectoderm cells; the blastocysts are immediately vitrified (frozen)
5Targeted genetic testingDNA amplification and analysis for the specific familial variant
6Embryo classificationEmbryos are classified as unaffected, carrier, affected or inconclusive
7Frozen embryo transfer (FET)Individualised endometrial preparation and transfer of an embryo selected after counselling

The pre-cycle phase is often the main bottleneck of the timeline. The ASRM guidance (2023, full text) says that custom test development is ideally completed before IVF begins, and the ESHRE recommendations (2020) also describe validation before clinical use.

Embryo banking means collecting and freezing embryos over more than one egg retrieval. The team may consider it in selected time-sensitive cases: especially when PGT-M is planned and only a few embryos are expected in each cycle, when age adds time pressure, or when treatment that threatens fertility lies ahead. Diminished ovarian reserve alone is not a sufficient reason to bank embryos. Banking has also not been clearly shown to raise the cumulative chance of a live birth in patients with low reserve. For patients preserving fertility before medically indicated treatment, the ASRM 2026 fertility-preservation opinion lists intended PGT-M among the possible reasons to consider more than one stimulation. Whether a cycle can start before the test is ready, and when biopsy can take place, has to be agreed with the specific PGT laboratory.

Why does preparation take time?

A PGT-M test is not an off-the-shelf laboratory panel. Human gene variants are diverse, so the genetics laboratory has to build and validate a custom diagnostic strategy for each couple.

That work includes reading (sequencing) the parents’ DNA, checking linkage markers (short, variable DNA segments that sit on either side of the gene) and preparing positive and negative control samples. Often the laboratory also needs DNA from the couple’s own parents or from an earlier child. This shows which copy of the chromosome carries the variant.

Preparation may take a few weeks to a few months, depending on the family, the variant and the laboratory. It helps reduce technical risks such as allele dropout (ADO), in which one copy of a gene is not copied (amplified) in the test. Ask the laboratory for a timeline specific to your case and for an explanation of how it handles an inconclusive result.

What PGT-M can and cannot do

It helps to know what the test can answer, and where its limits lie, before treatment starts.

What PGT-M can do:

What PGT-M cannot do:

In some cycles, all available embryos may be affected by the targeted condition, or may stop developing before biopsy. The ASRM guidance (2023) and ESHRE consortium data support discussing the possibility of no transferable embryo openly before stimulation medication begins.

Laboratory grades such as 4AA or 3BB describe how an embryo looks under the microscope, not its genetic health. Our guide to IVF embryo grading explains how to read them.

Why genetic counselling matters

Genetic counselling before treatment is a clinical conversation, not an administrative formality. A genetic counsellor can explain the inheritance pattern, the limits of the result and any incidental findings.

The same conversation covers choices that are easier to settle before the laboratory reports arrive. How will an inconclusive result—and, if PGT-A is also performed, a mosaic result (a mix of typical and atypical cells in the same sample)—be handled? In a recessive condition, would you consider transferring a healthy carrier embryo? Which clinical and legal rules apply to testing, storage and transfer in the country of treatment?

Settling them in advance, with the questions listed further down, means you will not have to decide in a hurry when the results arrive.

Practical planning for international patients

International planning usually starts with sending complete genetic records securely to the IVF team and the PGT laboratory. Their review shows which samples are needed, whether relatives need to take part and whether a visit is required for treatment, biopsy or transfer.

The timing of stimulation, biopsy, results and frozen embryo transfer varies between laboratories and treatment plans. Ask for a written, case-specific schedule before arranging travel. Complete laboratory reports, the exact name of the variant and earlier genetic counselling records can speed up that review.

Questions worth discussing before deciding

Bring these questions to your consultation with your fertility specialist and clinical geneticist:

  1. What is the exact name of our familial variant in HGVS notation (the standard system for naming gene variants), and is it confirmed in formal laboratory documents?
  2. Does the laboratory use direct sequencing, targeted PCR (copying one chosen DNA segment), or next-generation sequencing (NGS, reading many DNA segments at once) with linkage analysis?
  3. What inconclusive or failure rate has the laboratory reported for custom assays like ours?
  4. With our inheritance pattern, what is our clinic’s policy on transferring healthy carrier embryos?
  5. What is the plan if the first cycle produces no unaffected embryo?
  6. Why is confirmatory prenatal diagnosis (chorionic villus sampling [CVS] or amniocentesis) still offered during pregnancy, even after an unaffected PGT-M result?
  7. Which legal rules apply to embryo testing, storage time and single-embryo transfer in our treatment country?

Clinical note

PGT-M is targeted, but it cannot bring the chance of a diagnostic error down to zero. The residual risk depends on the variant, the available family markers and the laboratory method.

ASRM (2023) supports offering confirmatory prenatal diagnosis (CVS or amniocentesis) after PGT-M. ESHRE (2020) advises considering prenatal diagnosis before PGT-M starts and strongly recommends it in some situations. ACOG (2020) adds that when PGT-A was not done, screening or diagnostic testing for chromosomal abnormalities should be offered in pregnancy. An unaffected embryo result is valuable information; it does not mean that genetic diagnosis in pregnancy is unnecessary. Offering CVS or amniocentesis is not the same as requiring an invasive procedure—the decision follows genetic counselling and informed preference. NIPT (non-invasive prenatal testing) is a screening blood test and, in most situations, does not confirm the specific single-gene condition that PGT-M targeted.

The meaning of a carrier result depends on the inheritance pattern and the condition. In a classic autosomal recessive condition, an embryo with one disease-associated variant is usually an unaffected carrier. If only unaffected carrier embryos are available, transfer can be discussed after genetic counselling. A future child may be able to pass the variant on.

Test preparation should be discussed early. Embryo banking across more than one retrieval may be discussed in selected time-sensitive cases, and when few embryos are expected in each cycle. It is not a routine step for every patient with diminished ovarian reserve. The laboratory, IVF team and patients should agree on the testing and biopsy plan before it proceeds.

Related reading:

Frequently Asked Questions for Dr. Aksoy

Is PGT-M the same as PGT-A? What is the difference between them?

No, PGT-M and PGT-A are not the same test. Both are genetic tests applied to embryos in IVF treatment, but they look for different problems.

PGT-M checks whether a specific inherited disease known in the family has been passed on to the embryo. It can be used, for example, for thalassaemia, cystic fibrosis or some other single-gene diseases. The aim is to identify embryos that do not carry the disease or are not affected by it.

PGT-A evaluates the number of chromosomes in the embryo. For example, it looks for numerical chromosome abnormalities such as three copies of chromosome 21. However, PGT-A does not rule out the specific genetic diseases that PGT-M looks for. Also, PGT-A does not raise the chance of pregnancy or live birth in every patient.

One point matters: an embryo with a normal PGT-M result does not necessarily have all of its chromosomes normal. Likewise, an embryo with a normal PGT-A result cannot be said to be free of all inherited diseases. In some patients the two tests can be used together, but I do not think every IVF patient needs routine genetic testing. I decide which test is needed according to the couple’s genetic history and medical characteristics.

FAQ: more questions about PGT-M

Is PGT-M the same as standard IVF?

No. IVF creates the embryos. PGT-M adds a biopsy and a targeted test for a known inherited condition before transfer.

Does PGT-M mean a baby will be healthy?

No test can promise that. PGT-M lowers the chance of transferring an embryo affected by the targeted disorder. It does not assess every other genetic or health risk, and it cannot predict pregnancy or live birth.

Can PGT-M be done without knowing the exact familial variant?

Usually not. The laboratory first needs a clearly identified familial variant, or another validated strategy.

Can a cycle end with no transferable embryo?

Yes. Embryos may stop developing before biopsy, or all those tested may be affected. Discussing this possibility before stimulation helps you plan for it.

Sources

Next step

A question about your own case?

An article can set out the general picture, but not what applies to your own history. If you would like your situation looked at, you can send your questions and any previous reports to the medical team.

For privacy, please send only information needed for an initial reply. Ask the team which secure channel to use for medical reports or identity documents.

Request a medical review

Add as a Preferred Source on Google

You can add draksoyivf.com as one of your preferred health information sources on Google.

Add on Google
Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed ORCID LinkedIn

The content has been created by Dr. Senai Aksoy and medically approved.

Before getting in touch

Please note that certain services, such as sperm donation, egg donation, surrogacy and gender selection (without medical necessity), are not permitted under Turkish law.

We would like to inform you that our clinic strictly adheres to these regulations and does not offer any of these services.

Continue